Dermatology Made Easy is based on the most popular topics from DermNet NZ's vast array of material. The book combines the essential focus of the ‘Made Easy’ book series with the authority and knowledge base of DermNet NZ's unparalleled resources.
Author: Anoma Ranaweera B.V. Sc; PhD (Clinical Biochemistry, University of Liverpool, UK). Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, May 2015.
Imatinib mesylate (Gleevac®; USA and Glivec® Europe, New Zealand, from Novartis) is a small molecule inhibitor of ABL, KIT, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases. It is an FDA-approved oral treatment for chronic myeloid leukaemia, acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative disease, chronic eosinophilic leukaemia and metastatic/malignant gastrointestinal stromal tumours. Imatinib has also been used for the treatment of some skin conditions.
Reported uses of imatinib in dermatology include:
With the exception of dermatofibrosarcoma protuberans, all other off-label dermatology indications are based on isolated case reports and/or small, uncontrolled series.
Imatinib has also been used in generalised morphoea.
Imatinib has been suggested if certain C-kit mutations present in certain types of melanoma;
Imatinib has also been reported to have been used successfully for:
The most frequently reported adverse reactions (>30%) are:
Common skin changes that occur during treatment with imatinib include:
Less common reactions include:
Some skin changes may be related to underlying haematological conditions, their treatment and/or immunosuppression:
See the DermNet NZ bookstore
© 2018 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.